Jaguar Health Advances Clinical Trial for MVID Treatment

Jaguar Health, Inc. has announced a key development in its clinical trial for microvillus inclusion disease (MVID), a rare pediatric condition lacking approved therapies. The trial focuses on crofelemer, an oral solution aimed at reducing reliance on parenteral support (PS), crucial for MVID patients. The transition to the active treatment-only phase underscores longer-term safety and efficacy as pivotal targets.

MVID is marked by intestinal failure from early childhood, requiring daily PS for survival, often leading to liver and kidney issues. Crofelemer could potentially decrease PS needs, pending regulatory approval. Jaguar's trial, encompassing centers in the US, EU, and UAE, is poised to support a new drug application (NDA) by mid-2027.

As part of broader aims to tackle intestinal failures, Jaguar’s crofelemer is also in trials for adults with similar conditions. With orphan drug status already secured, Jaguar aligns its efforts toward pioneering treatments for these severe, life-long health concerns.